Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients.

ABSTRACT:

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) patients are at an elevated risk of developing severe coronavirus disease 2019 (COVID-19). The objective of this study was to assess antibody responses and safety profiles six months after the third dose of the inactivated acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in MASLD patients.

Methods

This study included MASLD patients and healthy volunteers without a history of SARS-CoV-2 infection. Blood samples were collected six months after receiving the third dose of the inactivated vaccine to measure the levels of neutralizing antibodies (NAbs) and anti-spike IgG antibodies against SARS-CoV-2.

Results

A total of 335 participants (214 MASLD patients and 121 healthy volunteers) w

SUBMITTER: Cui J 

PROVIDER: S-EPMC11441169 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature